Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Review ArticleTeaching Case Studies

18F-FDG PET/CT Findings in Portal Vein Thrombosis and Liver Metastases

Devaki Shilpa Surasi, Janis P. O’Malley and Pradeep Bhambhvani
Journal of Nuclear Medicine Technology September 2015, 43 (3) 229-230; DOI: https://doi.org/10.2967/jnmt.114.152777
Devaki Shilpa Surasi
Division of Molecular Imaging and Therapeutics, Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janis P. O’Malley
Division of Molecular Imaging and Therapeutics, Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pradeep Bhambhvani
Division of Molecular Imaging and Therapeutics, Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

18F-FDG PET/CT is a valuable noninvasive tool in oncologic imaging, and its application in the diagnosis of liver metastases has been very convincing. Both the sensitivity and the specificity of 18F-FDG PET/CT are high for detecting liver metastases from various tumors including colorectal, breast, and lung. Such liver metastases are typically 18F-FDG–avid. We present atypical 18F-FDG PET findings in a lung cancer patient with known liver metastases and PVT.

  • 18F-FDG PET/CT
  • hepatic metastases
  • portal vein thrombosis

Oncology patients are prone to thrombotic complications because of their hypercoagulable state. Our case report describes a patient with lung adenocarcinoma, liver metastases, and portal vein thrombosis (PVT). We present interesting PET and CT findings highlighting the lack of significant 18F-FDG uptake in liver metastases as well as demonstrating a geographic uptake pattern congruent with decreased hepatic attenuation from sequelae of PVT.

CASE REPORT

A 50-y-old man had stage IV lung adenocarcinoma, osseous metastases on bevacizumab (Avastin; Genentech) chemotherapy, and systemic anticoagulation for left calf vein thrombosis. He had a progressive increase in levels on liver function tests (alkaline phosphatase 260 [normal, 39–117], alanine transaminase 356 [normal, 15–58], aspartate transaminase 197 [normal, 14–40], lactate dehydrogenase 431 [normal, 120–240], and normal total bilirubin).

CT abdomen/pelvis (portal phase) demonstrated geographic areas of decreased attenuation involving the entire left hepatic lobe and segments of the posterior right hepatic lobe that were not consistent with metastases. No liver lesions suggestive of metastases were seen. The left hepatic lobe perfusion abnormality appeared secondary to left PVT. The posterior segmental abnormality was also attributed to a small-vessel portal occlusion, although no definite thrombus was seen.

PET/CT images (Fig. 1) revealed congruent intense hypermetabolic activity within the areas of hypoattenuation within the liver, suspected to be from PVT-related parenchymal inflammation or injury. Within the anterior hepatic segment, there were patchy areas of mild 18F-FDG uptake atypical of metastases. Rising liver function levels led to ultrasound-guided biopsy of this area, which revealed metastatic pulmonary adenocarcinoma. For progressive liver metastatic disease and PVT, his chemotherapy was modified, with good response and improved liver function. Follow-up CT demonstrated left hepatic lobe atrophy and cavernous transformation, sequelae of PVT.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

(A and B) Maximum-intensity-projection image of 18F-FDG PET/CT (A) and axial PET image (B) demonstrate geographic intense hypermetabolic activity within left hepatic lobe and posterior segment of right hepatic lobe (white asterisks) from PVT. Patchy uptake of 18F-FDG is noted in anterior hepatic segment (black arrow), which is atypical for metastases. (C) Axial contrast-enhanced CT (portal phase) shows congruent areas of hypoattenuation (black asterisks) and abrupt termination of left portal vein (white arrowhead) and posterior right portal vein (black arrowhead) from thrombosis. Incidental focal 18F-FDG activity in left lower chest on maximum-intensity-projection image was from pulmonary inflammation.

DISCUSSION

18F-FDG PET has been shown to be highly sensitive in detecting hepatic metastases from different primary tumors, seen most often as hypermetabolic lesions. PET/CT was shown to be superior to contrast-enhanced CT in the detection of untreated hepatic metastases in a prospective study evaluating 45 patients with various primary cancers. The sensitivity and specificity for the detection of hepatic metastases were 87.9% and 16.7%, respectively, for contrast-enhanced CT, and 97% and 75%, respectively, for PET/CT (1). However, not all hypermetabolic lesions are malignant. For example, abscesses, infections, and benign neoplasms such as adenomas and hemangioendotheliomas may be 18F-FDG–avid (2). A few 18F-FDG PET–negative hepatic metastases similar to those of our patient have also been reported in the literature and were due to either the small size of the lesion or the lower resolution of PET when used alone (3).

Our patient also had PVT, which could represent either a bland blood thrombus that is metabolically inactive or a tumor thrombus that is metabolically active. Common predisposing conditions for PVT include primary or secondary hepatobiliary malignancies, cirrhosis, abdominal sepsis, myeloproliferative disorders, and inherited thrombophilias. The mechanisms involved in the development of a neoplastic venous thrombosis include direct vascular invasion, compression by tumor mass, or the underlying hypercoagulable state.

Characteristic contrast-enhanced CT findings associated with PVT include lack of luminal enhancement, increased hepatic enhancement in the arterial phase, and decreased enhancement in the portal venous phase (4). Published literature supports the role of 18F-FDG PET/CT in differentiating 18F-FDG–avid tumor thrombus from a benign or bland thrombus that is not 18F-FDG–avid (5).

CONCLUSION

Interpretation of 18F-FDG uptake within the liver in patients with more than one pathologic condition can be challenging. In our patient, PET/CT was false-negative for liver metastases but demonstrated an interesting pattern of hypermetabolic activity in the hypoattenuating areas of the liver from PVT.

Footnotes

  • Published online Feb. 5, 2015.

REFERENCES

  1. 1.↵
    1. D’souza MM,
    2. Sharma R,
    3. Mondal A,
    4. et al
    . Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases. Nucl Med Commun. 2009;30:117–125.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Tan GJ,
    2. Berlangieri SU,
    3. Lee ST,
    4. Scott AM
    . FDG PET/CT in the liver: lesions mimicking malignancies. Abdom Imaging. 2014;39:187–195.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Rachh S,
    2. Basu S
    . PET/CT in patients with liver lesions of different nature. Clin Transl Imaging. 2014;2:139–155.
    OpenUrlCrossRef
  4. 4.↵
    1. Mathieu D,
    2. Vasile N,
    3. Grenier P
    . Portal thrombosis: dynamic CT features and course. Radiology. 1985;154:737–741.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Sharma P,
    2. Kumar R,
    3. Jeph S,
    4. et al
    . 18F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus? Nucl Med Commun. 2011;32:782–788.
    OpenUrlCrossRefPubMed
  • Received for publication December 5, 2014.
  • Accepted for publication January 23, 2015.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 43 (3)
Journal of Nuclear Medicine Technology
Vol. 43, Issue 3
September 1, 2015
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
18F-FDG PET/CT Findings in Portal Vein Thrombosis and Liver Metastases
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
18F-FDG PET/CT Findings in Portal Vein Thrombosis and Liver Metastases
Devaki Shilpa Surasi, Janis P. O’Malley, Pradeep Bhambhvani
Journal of Nuclear Medicine Technology Sep 2015, 43 (3) 229-230; DOI: 10.2967/jnmt.114.152777

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
18F-FDG PET/CT Findings in Portal Vein Thrombosis and Liver Metastases
Devaki Shilpa Surasi, Janis P. O’Malley, Pradeep Bhambhvani
Journal of Nuclear Medicine Technology Sep 2015, 43 (3) 229-230; DOI: 10.2967/jnmt.114.152777
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • CASE REPORT
    • DISCUSSION
    • CONCLUSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • High-Sensitivity Troponin Elevation in a Young Woman with Typical Chest Pain: The Heart of Matter
  • Prominent Right Ventricular Tracer Uptake: A Harbinger of Multivessel Coronary Artery Disease
  • SPECT/CT for Discrimination Between Active and Inactive Os Trigonum in Posterior Ankle Syndrome
Show more Teaching Case Studies

Similar Articles

Keywords

  • 18F-FDG PET/CT
  • hepatic metastases
  • portal vein thrombosis
SNMMI

© 2025 SNMMI

Powered by HighWire